Evidence map›Paper›PMID 39741436›Full record

ArticleThe American journal of psychiatry2025

Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity.

David E Olson

Abstract read
In one paragraph

Article in The American journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Trial
  2. Review
  3. Article
  4. Psychedelic therapy and postpartum depression: priorities and prospects.Therapeutic advances in psychopharmacology · 2026
    Review
  5. Review
  6. Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David E OlsonInstitute for Psychedelics and Neurotherapeutics, Department of Chemistry, Department of Biochemistry & Molecular Medicine, Center for Neuroscience, University of California, Davis, Davis, Calif.

Funding

High-throughput Identification of Non-hallucinogenic Psychoplastogens for Treating AddictionR01DA056365 · NIDA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI David E Olson · 2022 to 2026
$2.7M
NIDA NIH HHS R01 DA056365
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ketamineneuroplasticitypsychedelicpsychoplastogenSV2A

Identifiers

PMID39741436
PMCPMC11822763

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.